Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:391705.
doi: 10.5402/2012/391705. Epub 2012 Mar 20.

Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center

Olivier Riou  1 , Pascal Fenoglietto, Benoit Laliberté, Cathy Menkarios, Carmen Llacer Moscardo, Meng Huor Hay, Norbert Ailleres, Jean-Bernard Dubois, Xavier Rebillard, David Azria
Affiliations

Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center

Olivier Riou et al. ISRN Urol. 2012.

Abstract

Background. To assess the feasibility of salvage intensity-modulated radiation Therapy (IMRT) and to examine clinical outcome. Patients and Methods. 57 patients were treated with salvage IMRT to the prostate bed in our center from January, 2007, to February, 2010. The mean prescription dose was 68 Gy in 34 fractions. Forty-four patients received concomitant androgen deprivation. Results. Doses to organs at risk were low without altering target volume coverage. Salvage IMRT was feasible without any grade 3 or 4 acute gastrointestinal or urinary toxicity. With a median follow-up of 21 months, one grade 2 urinary and 1 grade ≥2 rectal late toxicities were reported. Biological relapse-free survival was 96.5% (2.3% (1/44) relapsed with androgen suppression and 7.7% (1/13) without). Conclusion. Salvage IMRT is feasible and results in low acute and chronic side-effects. Longer follow-up is warranted to draw conclusions in terms of oncologic control.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Average dose volume histogram for the first 10 patients.
See this image and copyright information in PMC

References

    1. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. International Journal of Radiation Oncology Biology Physics. 2000;48(2):369–375. - PubMed
    1. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. Journal of Clinical Oncology. 2007;25(15):2035–2041. - PMC - PubMed
    1. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostrate cancer recurrence after radical prostatectomy. Journal of Clinical Oncology. 2001;219(4):1030–1039. - PubMed
    1. Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology. 2001;219(2):432–439. - PubMed
    1. Wo JY, Chen MH, Nguyen PL, et al. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. Journal of Clinical Oncology. 2009;27(35):6000–6005. - PMC - PubMed

LinkOut - more resources